JOINT STEERING COMMITTEE

TERRY MAGNUSON, PH.D.

Terry Magnuson, PhD, is vice chancellor for research at UNC-Chapel Hill and the Sarah Graham Kenan Professor of genetics. He leads a campus-wide research program that attracts $1 billion in contract and grant funding, connects academic units across campus with university priorities, and oversees research support offices as well as 14 research centers and institutes.

Dr. Magnuson is a world-renowned geneticist who studies chromatin and gene expression in various diseases. He joined the UNC School of Medicine in 2000 to create its $245 million-backed genetics and genomics program and served as the founding chair of the genetics department in the UNC School of Medicine, and in 2010 he was named vice dean for research in the School of Medicine. He is a member of the National Institutes of Health Council of Councils, an exclusive group of the top minds in the nation charged with guiding research projects that transcend the National Institute of Health’s centers and institutes. He was appointed by the National Academies to establish guidelines for work with human embryonic stem cells and served as vice chair of the National Academy of Medicine committee evaluating the California Institute for Regenerative Medicine. He currently serves as vice president of the Genetics Society of America.

Read More Read Less

DHIREN THAKKER, PH.D.

Dhiren R. Thakker, PhD, is interim dean at the UNC Eshelman School of Pharmacy, interim director of the Eshelman Institute for Innovation, and the Howard Q. Ferguson Distinguished Professor of pharmacy. He has been a member of the school’s faculty for 22 years, during which time he served as the associate dean for research and graduate education and associate dean for entrepreneurial development and global engagement (EDGE). He joined the school after a career in research at the National Institutes of Health and in drug discovery and development at Glaxo, Inc., now GSK.

Dr. Thakker’s research is focused on metabolism by cytochrome P450 enzymes and intestinal transport of drugs, pediatric drug disposition, and the role of transporters on the antidiabetic and anticancer efficacy of the most prescribed drug, metformin. He is a co-founder and former member of the board for Qualyst, Inc., now Qualyst Transporter Solutions; co-founder and chair of the scientific advisory board of Sphaera Pharma; and a board member of Chesson Labs and Ternus Pharma. He is a fellow of the American Association for Pharmaceutical Scientists and has served as a co-editor of Medicinal Research Reviews and on the editorial boards the Journal of Pharmaceutical Sciences, Drug Metabolism and Disposition, and Current Drug Metabolism.

Read More Read Less

BLOSSOM DAMANIA, PH.D.

Blossom Damania, PhD, is vice dean for research at the UNC School of Medicine and the Boshamer Distinguished Professor of microbiology and immunology. She is also a member and co-director of the Virology and Global Oncology programs in the Lineberger Comprehensive Cancer Center at UNC-Chapel Hill.

Dr. Damania's research focuses on oncogenic human viruses, host-pathogen interactions and virus-associated cancers. She has received several honors for her work, including being named a V Foundation for Cancer Research Scholar, an AACR Gertrude B. Elion Research Scholar, a Burroughs Welcome Investigator in the Pathogenesis of Infectious Disease, an American Heart Established Investigator, and a Leukemia & Lymphoma Society Scholar. She was named a Kavli fellow of the National Academy of Science and a fellow of the American Academy of Microbiology. She served as a member for the Report on Carcinogens Monograph by the National Toxicology Program. Dr. Damania currently serves as senior editor for several academic journals and is also the chair of the National Cancer Institute (NCI) Board of Scientific Advisors on HIV/AIDS Malignancies.

Read More Read Less

BILL SLATTERY

Bill is a Partner in the Biotherapeutics group at Deerfield, which he joined in 2000. He began his professional career studying immune system complications associated with End Stage Renal Disease. Prior to joining Deerfield, Bill was a senior healthcare analyst between 1990 and 2000 at Amerindo Investment Advisors overseeing biotechnology investments. He has held various positions in research including those at National Medical Enterprises, Johnson & Johnson, and HMSS. Bill has a degree in Biology from State University of New York at Albany and completed coursework in Immunology at the Graduate School-New Brunswick, Rutgers University.

Read More Read Less

NICK BISHOP, PH.D.

Dr. Bishop is an Analyst in the Biotherapeutics group at Deerfield, and provides extensive research and analysis on individual companies operating in the healthcare industry. Prior to joining Deerfield in 2014, he spent four years as a research analyst covering the Biotech sector at Cowen and Company, where he was recognized as a Rising Star by Institutional Investor in 2013. Prior to entering the finance industry, Dr. Bishop was a biomedical research scientist at Harvard University and Massachusetts Institute of Technology. He has authored several scientific journal articles on the genetic regulation of aging and lifespan, one of which was featured as the cover story for an issue of Nature. Dr. Bishop received his B.A. with honors from Rice University and his Ph.D. from Massachusetts Institute of Technology.

Read More Read Less

JOE PEARLBERG, M.D. PH.D.

Dr. Pearlberg is the Vice President of Scientific Affairs and is in the Biotherapeutics group at Deerfield which he joined in July 2017. Prior to joining Deerfield, he was the Vice President of Clinical Development at Infinity Pharmaceuticals from December 2015 until July 2017. Prior to Infinity Pharmaceuticals, Dr. Pearlberg worked as a Medical Director in the oncology unit of Sanofi from November 2010 until September 2014. Dr. Pearlberg received his M.D. at the University of California, San Francisco, and completed his clinical training at the Massachusetts General Hospital and Dana Farber Cancer Institute. Dr. Pearlberg also received his Ph.D. in molecular biology from Harvard University and was a Lecturer in the Department of Biological Chemistry and Molecular Pharmacology at Harvard Medical School. He also holds a B.A. in Biochemistry from the University of Pennsylvania.

Read More Read Less

ALLIANCE MANAGEMENT

COMING SOON


TERRY MAGNUSON, PH.D.

Read More
Read Less

DHIREN THAKKER, PH.D.

Read More
Read Less

Terry Magnuson, PhD, is vice chancellor for research at UNC-Chapel Hill and the Sarah Graham Kenan Professor of genetics. He leads a campus-wide research program that attracts $1 billion in contract and grant funding, connects academic units across campus with university priorities, and oversees research support offices as well as 14 research centers and institutes.

Dr. Magnuson is a world-renowned geneticist who studies chromatin and gene expression in various diseases. He joined the UNC School of Medicine in 2000 to create its $245 million-backed genetics and genomics program and served as the founding chair of the genetics department in the UNC School of Medicine, and in 2010 he was named vice dean for research in the School of Medicine. He is a member of the National Institutes of Health Council of Councils, an exclusive group of the top minds in the nation charged with guiding research projects that transcend the National Institute of Health’s centers and institutes. He was appointed by the National Academies to establish guidelines for work with human embryonic stem cells and served as vice chair of the National Academy of Medicine committee evaluating the California Institute for Regenerative Medicine. He currently serves as vice president of the Genetics Society of America.

Dhiren R. Thakker, PhD, is interim dean at the UNC Eshelman School of Pharmacy, interim director of the Eshelman Institute for Innovation, and the Howard Q. Ferguson Distinguished Professor of pharmacy. He has been a member of the school’s faculty for 22 years, during which time he served as the associate dean for research and graduate education and associate dean for entrepreneurial development and global engagement (EDGE). He joined the school after a career in research at the National Institutes of Health and in drug discovery and development at Glaxo, Inc., now GSK.

Dr. Thakker’s research is focused on metabolism by cytochrome P450 enzymes and intestinal transport of drugs, pediatric drug disposition, and the role of transporters on the antidiabetic and anticancer efficacy of the most prescribed drug, metformin. He is a co-founder and former member of the board for Qualyst, Inc., now Qualyst Transporter Solutions; co-founder and chair of the scientific advisory board of Sphaera Pharma; and a board member of Chesson Labs and Ternus Pharma. He is a fellow of the American Association for Pharmaceutical Scientists and has served as a co-editor of Medicinal Research Reviews and on the editorial boards the Journal of Pharmaceutical Sciences, Drug Metabolism and Disposition, and Current Drug Metabolism.


BLOSSOM DAMANIA, PH.D.

Read More
Read Less

BILL SLATTERY

Read More
Read Less

Blossom Damania, PhD, is vice dean for research at the UNC School of Medicine and the Boshamer Distinguished Professor of microbiology and immunology. She is also a member and co-director of the Virology and Global Oncology programs in the Lineberger Comprehensive Cancer Center at UNC-Chapel Hill.

Dr. Damania's research focuses on oncogenic human viruses, host-pathogen interactions and virus-associated cancers. She has received several honors for her work, including being named a V Foundation for Cancer Research Scholar, an AACR Gertrude B. Elion Research Scholar, a Burroughs Welcome Investigator in the Pathogenesis of Infectious Disease, an American Heart Established Investigator, and a Leukemia & Lymphoma Society Scholar. She was named a Kavli fellow of the National Academy of Science and a fellow of the American Academy of Microbiology. She served as a member for the Report on Carcinogens Monograph by the National Toxicology Program. Dr. Damania currently serves as senior editor for several academic journals and is also the chair of the National Cancer Institute (NCI) Board of Scientific Advisors on HIV/AIDS Malignancies.

Bill is a Partner in the Biotherapeutics group at Deerfield, which he joined in 2000. He began his professional career studying immune system complications associated with End Stage Renal Disease. Prior to joining Deerfield, Bill was a senior healthcare analyst between 1990 and 2000 at Amerindo Investment Advisors overseeing biotechnology investments. He has held various positions in research including those at National Medical Enterprises, Johnson & Johnson, and HMSS. Bill has a degree in Biology from State University of New York at Albany and completed coursework in Immunology at the Graduate School-New Brunswick, Rutgers University.


NICK BISHOP, PH.D.

Read More
Read Less

JOE PEARLBERG, M.D. PH.D.

Read More
Read Less

Dr. Bishop is an Analyst in the Biotherapeutics group at Deerfield, and provides extensive research and analysis on individual companies operating in the healthcare industry. Prior to joining Deerfield in 2014, he spent four years as a research analyst covering the Biotech sector at Cowen and Company, where he was recognized as a Rising Star by Institutional Investor in 2013. Prior to entering the finance industry, Dr. Bishop was a biomedical research scientist at Harvard University and Massachusetts Institute of Technology. He has authored several scientific journal articles on the genetic regulation of aging and lifespan, one of which was featured as the cover story for an issue of Nature. Dr. Bishop received his B.A. with honors from Rice University and his Ph.D. from Massachusetts Institute of Technology.

Dr. Pearlberg is the Vice President of Scientific Affairs and is in the Biotherapeutics group at Deerfield which he joined in July 2017. Prior to joining Deerfield, he was the Vice President of Clinical Development at Infinity Pharmaceuticals from December 2015 until July 2017. Prior to Infinity Pharmaceuticals, Dr. Pearlberg worked as a Medical Director in the oncology unit of Sanofi from November 2010 until September 2014. Dr. Pearlberg received his M.D. at the University of California, San Francisco, and completed his clinical training at the Massachusetts General Hospital and Dana Farber Cancer Institute. Dr. Pearlberg also received his Ph.D. in molecular biology from Harvard University and was a Lecturer in the Department of Biological Chemistry and Molecular Pharmacology at Harvard Medical School. He also holds a B.A. in Biochemistry from the University of Pennsylvania.

ALLIANCE MANAGEMENT


COMING SOON